Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Operating Income (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Operating Income data on record, last reported at -$10.9 million in Q3 2025.

  • For Q3 2025, Operating Income rose 0.67% year-over-year to -$10.9 million; the TTM value through Sep 2025 reached -$43.4 million, up 6.44%, while the annual FY2024 figure was -$45.4 million, 29.74% up from the prior year.
  • Operating Income reached -$10.9 million in Q3 2025 per ASMB's latest filing, up from -$11.1 million in the prior quarter.
  • Across five years, Operating Income topped out at -$9.9 million in Q1 2025 and bottomed at -$62.9 million in Q4 2021.
  • Average Operating Income over 5 years is -$19.4 million, with a median of -$17.5 million recorded in 2023.
  • Peak YoY movement for Operating Income: crashed 459.72% in 2021, then soared 63.46% in 2022.
  • A 5-year view of Operating Income shows it stood at -$62.9 million in 2021, then skyrocketed by 63.46% to -$23.0 million in 2022, then skyrocketed by 45.38% to -$12.6 million in 2023, then increased by 8.12% to -$11.5 million in 2024, then increased by 5.63% to -$10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$10.9 million in Q3 2025, -$11.1 million in Q2 2025, and -$9.9 million in Q1 2025.